Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/IGF1R_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IGF1R_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IGF1R_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/IGF1R_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IGF1R_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/IGF1R_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IGF1R_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/IGF1R_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/IGF1R_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IGF1R_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00310989 | Endometrium | AEH | stress-activated protein kinase signaling cascade | 51/2100 | 247/18723 | 1.12e-05 | 2.52e-04 | 51 |
GO:00328728 | Endometrium | AEH | regulation of stress-activated MAPK cascade | 42/2100 | 192/18723 | 1.53e-05 | 3.23e-04 | 42 |
GO:00434105 | Endometrium | AEH | positive regulation of MAPK cascade | 84/2100 | 480/18723 | 2.19e-05 | 4.25e-04 | 84 |
GO:00703028 | Endometrium | AEH | regulation of stress-activated protein kinase signaling cascade | 42/2100 | 195/18723 | 2.27e-05 | 4.35e-04 | 42 |
GO:00329848 | Endometrium | AEH | protein-containing complex disassembly | 45/2100 | 224/18723 | 7.16e-05 | 1.10e-03 | 45 |
GO:19016539 | Endometrium | AEH | cellular response to peptide | 64/2100 | 359/18723 | 1.16e-04 | 1.63e-03 | 64 |
GO:00518974 | Endometrium | AEH | positive regulation of protein kinase B signaling | 28/2100 | 120/18723 | 1.20e-04 | 1.67e-03 | 28 |
GO:003367414 | Endometrium | AEH | positive regulation of kinase activity | 78/2100 | 467/18723 | 2.03e-04 | 2.54e-03 | 78 |
GO:004343410 | Endometrium | AEH | response to peptide hormone | 70/2100 | 414/18723 | 2.93e-04 | 3.35e-03 | 70 |
GO:00480092 | Endometrium | AEH | insulin-like growth factor receptor signaling pathway | 12/2100 | 37/18723 | 4.83e-04 | 4.97e-03 | 12 |
GO:00439546 | Endometrium | AEH | cellular component maintenance | 16/2100 | 61/18723 | 8.71e-04 | 8.04e-03 | 16 |
GO:00328699 | Endometrium | AEH | cellular response to insulin stimulus | 37/2100 | 203/18723 | 1.97e-03 | 1.54e-02 | 37 |
GO:00713758 | Endometrium | AEH | cellular response to peptide hormone stimulus | 49/2100 | 290/18723 | 2.24e-03 | 1.72e-02 | 49 |
GO:00518965 | Endometrium | AEH | regulation of protein kinase B signaling | 34/2100 | 185/18723 | 2.55e-03 | 1.88e-02 | 34 |
GO:00508086 | Endometrium | AEH | synapse organization | 67/2100 | 426/18723 | 2.67e-03 | 1.94e-02 | 67 |
GO:004340910 | Endometrium | AEH | negative regulation of MAPK cascade | 33/2100 | 180/18723 | 3.04e-03 | 2.15e-02 | 33 |
GO:00434914 | Endometrium | AEH | protein kinase B signaling | 37/2100 | 211/18723 | 3.89e-03 | 2.64e-02 | 37 |
GO:00082866 | Endometrium | AEH | insulin receptor signaling pathway | 23/2100 | 116/18723 | 4.58e-03 | 2.95e-02 | 23 |
GO:00328689 | Endometrium | AEH | response to insulin | 44/2100 | 264/18723 | 4.70e-03 | 3.00e-02 | 44 |
GO:00072546 | Endometrium | AEH | JNK cascade | 30/2100 | 167/18723 | 6.16e-03 | 3.70e-02 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGF1R | SNV | Missense_Mutation | novel | c.899A>G | p.Asp300Gly | p.D300G | P08069 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
IGF1R | SNV | Missense_Mutation | | c.199N>T | p.Ala67Ser | p.A67S | P08069 | protein_coding | tolerated(0.14) | benign(0.011) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
IGF1R | SNV | Missense_Mutation | | c.55C>G | p.Leu19Val | p.L19V | P08069 | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
IGF1R | SNV | Missense_Mutation | | c.2431G>C | p.Glu811Gln | p.E811Q | P08069 | protein_coding | tolerated(0.7) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
IGF1R | SNV | Missense_Mutation | novel | c.3131G>T | p.Arg1044Met | p.R1044M | P08069 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGF1R | SNV | Missense_Mutation | | c.1099N>T | p.Gly367Trp | p.G367W | P08069 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGF1R | SNV | Missense_Mutation | | c.3003N>A | p.Met1001Ile | p.M1001I | P08069 | protein_coding | tolerated(0.44) | benign(0.007) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IGF1R | SNV | Missense_Mutation | novel | c.2026N>T | p.Gly676Cys | p.G676C | P08069 | protein_coding | tolerated(0.08) | benign(0.01) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
IGF1R | SNV | Missense_Mutation | | c.1828G>A | p.Val610Ile | p.V610I | P08069 | protein_coding | tolerated(0.09) | benign(0.009) | TCGA-BH-A0C3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
IGF1R | SNV | Missense_Mutation | novel | c.3938C>T | p.Ser1313Phe | p.S1313F | P08069 | protein_coding | tolerated(0.06) | possibly_damaging(0.474) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | | OSI-906 | LINSITINIB | |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | antibody | AMG-479 | GANITUMAB | |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | | VPI-2690B | | |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | | Somatomedin-1 | | |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | | SB-202190 | SB-202190 | |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | antibody | GANITUMAB | GANITUMAB | |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | antibody | FIGITUMUMAB | FIGITUMUMAB | |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | antibody | 310264711 | ISTIRATUMAB | |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | | TT-100 | | |
3480 | IGF1R | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE | agonist | CHEMBL1201716 | MECASERMIN | |